Mylan and Biocon launch Herceptin biosimilar in US

Mylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast and stomach cancer blockbuster.

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

Daiichi Sankyo takes Seattle Genetics to court as battle ove...

Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen

Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

AZ/Daiichi's possible breast cancer blockbuster gets fast US...

The FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, setting up a possible launch as early as Q2 next year.

NICE says 'no' to regular NHS funding for Roche's Tecentriq ...

NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it